Clinical Trial Update: Safety Study of EF-022 ( Modified Vitamin D Binding Protein Macrophage Activator) in Subjects With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the safety of EF-022, a Modified Vitamin D Binding Protein Macrophage Activator, in subjects with advanced solid tumors has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• EF-022

Snippet

Sponsor: Efranat Ltd. | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED